The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

Novo Nordisk announced a major price reduction for two of its insulin products. Starting in January 2026, the list price of Fiasp will drop by 75%, while Tresiba will see a 72.2% reduction.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

Novo Nordisk made a submission to the U.S. Food and Drug Administration (FDA) nominating Novo Nordisk’s semaglutide ...

NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term ...

Financial writer sees Novo Nordisk's stock drop as a buying opportunity after disappointing trial results, citing strong ...